Top 5 Stories of 2018

December 19, 2018

The most-read stories on Psych Congress Network in 2018:


Cannabis Lightens Mood, but May Worsen Depression Over Time

Smoking cannabis eases symptoms of depression, anxiety, and stress shortly after use, but depressive symptoms are likely to worsen over time, according to a study published online in the Journal of Affective Disorders.


Ketamine Effective as Maintenance Treatment for Anxiety

In patients with treatment-refractory anxiety who responded to ketamine, weekly maintenance doses over 3 months were well tolerated and significantly improved social and work functioning, according to a small study published online in the Journal of Psychopharmacology.


Meta-analysis Names Most Effective Atypicals in Bipolar Depression

Cariprazine, lurasidone, olanzapine, combination olanzapine-fluoxetine, and quetiapine are significantly more effective than placebo in easing symptoms of acute bipolar depression, according to a meta-analysis.


Novel Depression Drug Awarded FDA's Breakthrough Therapy Designation

A novel drug being developed for the treatment of major depressive disorder (MDD) has been awarded Breakthrough Therapy designation from the US Food and Drug Administration (FDA), following positive results in a Phase 2 trial.


FDA Approves First Monthly Injectable for Bipolar Disorder

The US Food & Drug Administration (FDA) has approved a new indication for Abilify Maintena (aripiprazole), making it the first once-monthly, long-acting injectable approved for maintenance monotherapy treatment of bipolar I disorder in adults.